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Abstract
Objective—Ileo-cecal resection (ICR) is common in Crohn’s disease (CD). Inflammation and
fibrosis frequently recur at the site of anastomosis or in the small intestine (SI). No animal models
of post-surgical inflammation and fibrosis exist. We developed a model of ICR in IL-10 null and
wild-type (WT) mice to test the hypothesis that that ICR promotes post-surgical inflammation and
fibrosis in SI or anastomosis of genetically susceptible IL-10 null, but not WT or germ free (GF)-
IL-10 null mice.
Design—GF-IL-10 null mice were conventionalized (CONV) and 3 weeks later randomized to ICR,
transection (T) or no treatment (NoTx). Age-matched conventionally raised (CONV) WT and GF-
IL-10 null mice received ICR, T or NoTx. Animals were killed 28 days later.
Main outcome measures—Histological scoring, real-time PCR for TNFα and collagen, and
immunostaining for CD3+ T cells, assessed inflammation and fibrosis.
Results—After ICR, CONV-IL-10 null, but not CONV-WT mice, developed significant
inflammation and fibrosis in SI and inflammation in anastomosis compared to NoTx or T controls.
Fibrosis occurred in anastomosis of both CONV-IL-10 null and CONV-WT following ICR. GF-
IL-10 null mice developed little or no inflammation or fibrosis in SI or anastomosis after ICR.
Conclusions—ICR in CONV-IL-10 null mice provides a new animal model of post-surgical
inflammation and fibrosis in SI and anastomosis. Absence of inflammation and fibrosis in SI of
CONV-WT and GF-IL-10 null following ICR indicates that post-surgical small bowel disease occurs
only in genetically susceptible IL-10 null mice and is bacteria dependent.
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Crohn’s Disease (CD) is an incurable inflammatory bowel disease (IBD) [1,2]. CD involves
chronic inflammation of the intestine, damage and distortion of tissue architecture and loss of
digestive, absorptive and motility functions. Disease onset commonly occurs in the ileum and
cecum. Inflammation is transmural in CD, and is associated with transmural increases in
collagen deposition, thickening of the muscularis layers, and fibrosis, which can lead to stenosis
and bowel obstruction [3,4]. As many as 65% of CD patients require surgical intervention for
unmanageable inflammation or fibrostenosing disease and many require repeat surgery for
recurrent disease [5,6]. Ileo-cecal resections (ICR) are common surgical interventions in CD
and are associated with high rates of disease recurrence [6]. After ICR or other surgeries,
recurrent inflammation or fibrosis typically occurs at the anastomosis and in small intestine
(SI) immediately upstream of the anastomosis [5,6,7,8,9,10]. Current therapies do not
effectively prevent post-surgical recurrence of CD and there are no approved or effective
medical therapies for fibrostenosing disease [6]. Major challenges in developing or testing new
therapies, are the inherent heterogeneity of CD at surgery, variable definitions of recurrence
and duration of follow-up and the fact that endoscopic evaluation of recurrent disease may not
fully inform about fibrosis [4,6,7,8,9,10]. An animal model would offer a well-controlled
experimental system to address mechanisms of post-surgical inflammation and fibrosis in small
bowel or anastomosis, and to test therapies.
Available evidence suggests that commensal microflora initiate and perpetuate IBD in
genetically susceptible hosts [11,12,13]. Antibiotics have proved useful as therapies for
specific complications of CD such as localized peritonitis, bacterial overgrowth due to stricture
and during drainage therapy for abscesses and perianal disease [14,15,16,17,18]. More limited
evidence implicates microflora in post-surgical CD. In small numbers of patients, antibiotics
have reduced postoperative disease recurrence [18,19] or promoted remission of ileocolonic
anastomosis disease [20]. One study reported that ICR altered the profile of ileal microflora
and that recurrent disease was associated with a high prevalence of adherent E. coli,
enterococci, bacteroides, and fusobacteria [21]. Very little is known about the in vivo roles of
microflora in fibrosis associated with CD or post-surgical fibrosis, despite in vitro evidence
that bacterial ligands stimulate proliferation and collagen accumulation in intestinal
mesenchymal cells [22].
Numerous animal models of IBD exist [11,23]. The IL-10 null model has some features in
common with CD [11,23]. Germ free IL-10 null mice do not develop disease. Colonization of
GF-IL-10 null mice with microflora from conventionally raised animals reliably initiates
disease, in cecum and colon, with a highly reproducible time course and location [24].
Ciprofloxacin and metronidazole improve disease in CONV-IL-10 null mice [24], and each
antibiotic preferentially affects cecal or colonic disease [24]. This is consistent with findings
that different bacteria initiate inflammation in either the cecum or colon of IL-10 null mice
[25]. One limitation of IL-10 null mice as a model of CD is that these animals do not typically
develop small bowel disease.
Recently, we applied ICR to wild-type C57BL6 mice [26]. In the current study we applied ICR
to CONV-IL-10 null mice and CONV-WT mice on the 129SvEv background. We tested the
hypothesis that ICR may promote post-surgical inflammation or fibrosis in the small intestine
or anastomosis of genetically susceptible IL-10 null, but not wild-type mice. We chose the
IL-10 null mouse to develop a model of post-surgical inflammation and fibrosis because of its
wide acceptance as an animal model with relevance to human IBD and the availability of germ-
free IL-10 null mice. We successfully adapted the ICR model to germ-free IL-10 null mice to
definitively test whether enteric microflora promote post-surgical inflammation or fibrosis.
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ICR in IL-10 null or WT mice
Eight week old germ free (GF) 129SvEv IL-10 null mice were obtained from the UNC
gnotobiotic rodent facility. Animals were transferred to specific pathogen free housing and
colonized with fecal slurries from conventionally raised mice as previously described [24].
Three weeks later, when colonization reproducibly initiates disease in the cecum and to a lesser
extent colon [24], mice were randomized to sham-operation (T), ileo-cecal resection (ICR) or
no surgery (NoTx) groups. Aged matched, conventionally raised WT 129SvEv (CONV-WT)
mice were obtained from Jackson labs, Maine, and assigned to NoTx, T or ICR groups. All
study groups were given liquid diet (Micro-Stablized Rodent Liquid Diet 101/101A, Purina
Mills, MO) 2 days before and 7 days after the start of the experiment. Liquid diet minimizes
complications that can occur post-operatively due to obstruction at the anastomosis by solid
fecal material [26,27]. Surgeries were performed under sterile conditions with the aid of the
operating microscope (7X magnification). Sham operations (T) consisted of transection and
re-anastomosis of bowel approximately 12 cm proximal to the ileocecal junction. For ICR,
small bowel was divided 12 cm proximal to the ileocecal junction and at the proximal colon
2–3 cm distal to the cecum. The mesentery was ligated and the intervening SI, cecum and
proximal colon removed (Figure 1). Intestinal continuity was restored using an end-to-end,
single layered anastomosis with interrupted 9-0 monofilament sutures. Mice were rehydrated
with 1–2 ml of warm intraperitoneal saline and the abdomen was closed with running suture.
Survival of surgery was 90% for IL-10 null and 87% for WT. The few animals that died or
required euthanasia did so within 2–4 days after surgery and were not included in the analyses.
GF-IL-10 null mice were obtained from the same UNC colony as animals that were
conventionalized before surgery. Surgery was performed as described above but in a
customized GF surgical isolator equipped with a port that permits sterile transfer of mice
directly from isolator to hood. Liquid diet was sterilized by irradiation. Pilot studies in CONV-
mice, verified that sterile diets result in identical weight gain as non-sterile diets. To verify GF
status after surgery, fur and fecal swabs were collected at 4 and 7 days after surgery and from
co-housed NoTx controls. Fecal samples were collected weekly thereafter. Aerobic and
anaerobic cultures, Gram stains, and culture for molds, performed by our gnotobiotic facility
[24,25], verified lack of contamination. Enlarged cecum in GF-IL-10 null mice given T or
NoTx, co-housed with ICR animals, provided an additional measure that GF status was retained
after surgery. Culture and Gram stains of feces collected at tissue harvest were uniformly
negative. Survival of GF-IL-10 null mice after surgery was 87%.
Tissue collection
Analyses focused on mice subject to ICR or T, and NoTx at 28 days after surgery to study the
chronic responses to surgery rather than immediate, acute inflammation or wound healing
responses to surgery. A subset of CONV IL-10 null and WT animals were also studied at 7
and 14 days after ICR to assess the time course of post-surgical inflammation. Animals were
weighed, anesthetized and killed and entire small bowel and colon were dissected. A one cm
segment spanning the anastomosis and two one cm segments of small intestine proximal to the
anastomosis were collected for histology or RNA extraction (Figure 1). A segment of colon
was collected from CONV-IL-10 null mice after ICR, T or NoTx for histological scoring of
colitis. Histology samples were fixed in 10% formalin and paraffin embedded and samples for
RNA were frozen.
Histological scoring of inflammation and fibrosis
Coded hematoxylin and eosin sections were scored for inflammation by an observer blinded
to treatments. Scoring used a well-validated system developed for IL-10 null mice [25], which
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assigns a score of 0 – 4 for inflammation and mucosal damage based on degree and extent of
transmural inflammation, goblet cell depletion and architecture distortion. Sections were
stained with Sirius red to visualize collagen accumulation and scored for fibrosis using a
validated scoring system as detailed in [28]. Briefly, experimental sections were compared
with Sirius red stained sections of normal small intestine and scored on a scale of 0–5 for
increased extent of collagen deposition throughout different layers of the bowel wall,
multiplied by percent of section involved (1=< 25%; 2=<50%, 3=<75% and 4=<100%), or
intensity of staining (1=no increase and 2=increased intensity). In prior studies [28], fibrosis
scores showed highly significant correlation with biochemical measures of fibrosis based on
collagen mRNA or protein.
Assays of TNFα and collagen mRNA abundance
TNFα and procollagen α1( I) mRNAs were quantified as independent measures of
inflammation and fibrosis. Total RNA was extracted using TRIZOL (Invitrogen, CA). Four
micrograms of DNAse treated (TurboDNA, Ambion, TX) RNA was reverse transcribed into
cDNA using oligodT primers, reverse transcriptase (Promega, WI) and standard conditions.
TNFα and collagen mRNA abundance was assessed using quantitative real-time PCR (qRT-
PCR) performed on the Rotorgene (Corbett Instruments, Sydney, Australia) using Syber green
reagent (Sigma-Aldrich, MO) and cycling conditions optimized for each primer and probe set.
Primers were as follows: TNFα: F: 5′-CTGTCTACTGAACTTCGGGGTGAT-3′; R: 5′-
GGTCTGGGCCATAGAACTGATG-3′ and procollagen α1(I): F: 5′-
GGTATGCTTGATCTGTATCTGC-3′; R: 5′-AGTCCAGTTCTTCATTGCATT-3′ and
Hydroxymethylbilane synthase (HMBS), F: 5′-TGTGTTGCACGATCCTGAAAC-3′ and R:
5′-CTCCTTCCAGGTGCCTCAGAA-3′ was used as a constitutively expressed housekeeping
control. All test samples in given comparison groups were run in the same qRT-PCR assay,
together with a standard curve comprising serial 10-fold dilutions of known concentrations of
product. Cycle thresholds for each test mRNA were normalized to HMBS using Rotorgene
software (Corbett, Australlia). Abundance of TNFα and collagen mRNAs were expressed as
fold-change from the mean expression levels in wild type mice given no treatment.
Immunohistochemistry for CD3, to detect T-cells
5μm sections were de-paraffinized and antigen retrival performed using Tris-Triton buffer
pH7.6 before overnight incubation at 4°C with rabbit anti-CD3 (A0452 Dako, Denmark)
diluted 1:200 with 5% normal goat serum in Tris-Triton buffer. Samples were incubated for
60 min at room temperature with goat anti-rabbit (111-065-144, Jackson) diluted 1:500 with
Tris-Triton buffer. Immunostaining was visualized using avidin-biotin DAB kit (Zymed/
Invitrogen cat#00-2014).
Statistics
All data are expressed as mean ± standard error. ANOVA was used to test for statistical
differences across groups. Tukeys test was used for post-hoc pair-wise comparisons and
statistical significance was set at p≤0.05.
RESULTS
Ileo-cecal resection (ICR) results in inflammation in the small intestine and anastomosis of
CONV IL-10 null, but not WT mice
Figure 2 shows representative photographs of entire bowel of CONV-WT or CONV-IL-10 null
mice after T or ICR. Note the evident cecal and colonic inflammation in CONV-IL-10 null
mice given T but normal small bowel. Note the evident inflammation in small intestine and at
anastomosis of CONV-IL-10 null mice but not WT after ICR. Figure 3 shows histological
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inflammation scores for small intestine and anastomosis of CONV-WT and CONV-IL-10 null
mice given NoTx, T or ICR. In WT mice at 28 days following ICR, inflammation scores in
small intestine and anastomosis were low and did not differ significantly from T or NoTx
controls. IL-10 null mice showed significantly increased inflammation scores in both the small
intestine and anastomosis compared with IL-10 null given T or NoTx. Inflammation scores for
small intestine and anastomosis of un-operated IL-10 null mice, or animals given transection,
did not differ significantly from WT mice, consistent with previous studies demonstrating lack
of small bowel disease in un-operated CONV IL-10 null mice [29]. Thus, development of
inflammation in small intestine and anastomosis after ICR occurs only in genetically
susceptible IL-10 null mice. Scoring of inflammation in colon confirmed colitis in CONV-
IL-10 null mice and revealed that ICR or T did not affect disease severity in colon (colitis
scores: NoTx 2.8 ± 0.4; T 2.4 ± 0.5; ICR 2.5 ± 0.4). Photomicrographs of representative H&E
stained sections in small intestine of CONV-IL-10 null mice after ICR (Figure 4) illustrate
transmural inflammation (Fig. 4A and 4B) and infiltration of small intestine with CD3+ T cells
ICR (Fig. 4C). Representative photomicrographs of the anastomosis demonstrate inflammation
in IL-10 null and not WT mice after ICR (Figure 4B). Figure 5 shows low and high power
histology in small intestine of CONV-IL-10 null mice at 7, 14 and 28 days after ICR compared
with WT at 7 days after ICR. Note the transmural inflammation in CONV-IL-10 null mice at
7 and 14 as well as 28 days after ICR with no evidence for inflammation in WT at 7 days
(Figure 5) or other times. Subsequent studies focused on the 28 day time point.
TNFα mRNA is up-regulated in SI and anastomosis of CONV IL-10 null, but not WT mice after
ICR
In small intestine and anastomosis real-time qRT-PCR revealed significantly increased
TNFα mRNA abundance in IL-10 null mice after ICR compared with all other IL-10 null or
WT groups (Figure 6). These biochemical data verify histological inflammation scores.
ICR-induced fibrosis of small intestine, but not anastomosis, is restricted to CONV-IL-10 null
mice
In small intestine of CONV-WT mice, neither ICR nor T significantly increased fibrosis scores
compared with NoTx controls (Figure 7). CONV-IL-10 null mice showed major increases in
fibrosis scores in small intestine after ICR whereas control transection did not result in fibrosis
of small intestine. The anastomosis showed a different pattern. After ICR, significant fibrosis
was observed at the anastomosis of both CONV-WT and CONV-IL-10 null mice (Figure 7).
In mice given T, mean anastomosis fibrosis scores in both IL-10 null and WT were higher than
but not significantly different than scores in untreated small intestine which reflected high inter-
animal variability. These results indicate that fibrosis at the anastomosis is likely a consequence
of ICR or surgical manipulation and is not influenced by IL-10 deficiency. Figure 8 shows
representative Sirius red stained sections to illustrate fibrosis in small intestine of only CONV-
IL-10 null mice after ICR, but fibrosis at anastomosis of CONV-WT and CONV-IL-10 null
mice after ICR or T.
Collagen mRNAs are up-regulated in SI of CONV-IL-10 null, but not WT mice after ICR
In small intestine RT-qPCR revealed significantly increased levels of procollagen α1(I)
mRNAs in IL-10 null mice after ICR compared with all other groups (Figure 9). These results
provide important biochemical confirmation of histological scoring data. At the anastomosis
RT-qPCR did not reveal an increase in collagen mRNA in WT or IL-10 null mice after T or
ICR compared with NoTx controls (Figure 9). IGF-I and TGFβ mRNA assays revealed no
close correlation between expression levels of these fibrogenic mediators and collagen mRNA
or fibrosis scores within small intestine or anastomosis (supplemental Figure 1).
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ICR does not induce post-surgical inflammation in small intestine or anastomosis of GF-IL-10
null mice
In small intestine of GF-IL-10 null mice, in contrast to small intestine of CONV-IL-10 null
mice, ICR did not lead to a significant increase in inflammation scores (Figure 10). While GF
IL-10 null mice showed higher mean inflammation scores at the anastomosis following ICR,
this was not statistically significant. Inflammation scores in small intestine of GF-IL-10 null
mice after ICR were significantly lower than in small intestine of CONV-IL-10 null mice after
ICR, and a similar pattern was observed at the anastomosis (Figure 10). Photomicrographs of
representative H&E stained sections are shown in Figure 11A. CD3 staining for T-cells showed
no evidence of increased T-cell infiltration into small intestine of GF-IL-10 null mice after ICR
(Figure 11B). Together these data demonstrate that commensal microflora is required to initiate
post-surgical small bowel inflammation in IL-10 null mice.
Reduced post-surgical fibrosis in small intestine and anastomosis of GF compared with
CONV IL-10 null mice
In GF-IL-10 null mice neither ICR nor T induced significant increases in fibrosis scores in
small intestine, and fibrosis scores were significantly higher in small intestine of CONV versus
GF-IL-10 null mice after ICR (Figure 12). Fibrosis scores at the anastomosis of a few GF
animals receiving either T (3 out of 8 animals) or ICR (1 out of 7 animals) were higher than
mean NoTx fibrosis scores. However, overall mean anastomosis fibrosis scores in GF- IL-10
null mice given ICR or T were significantly lower than in CONV IL-10 null mice given ICR
(Figure 12) suggesting that bacteria promote fibrotic responses at the site of surgery. Figure
13 shows representative photomicrographs of Sirius red stained sections to illustrate little or
no fibrosis in small intestine of GF IL-10 null mice following ICR, compared with NoTx, or
T, and mild fibrosis at anastomosis in a subset of GF-IL-10 null mice given T or ICR. However
comparisons of Figure 8 and 13 demonstrate much more dramatic fibrosis in CONV IL-10 null
mice after ICR.
Discussion
The primary goal of this study was to develop an animal model of post-surgical small bowel
inflammation and fibrosis. Using three independent measures, histological scoring, TNFα
mRNA abundance and T cell infiltration, we provide evidence that ICR results in sustained
post-surgical inflammation in the small intestine and anastomosis of CONV-IL-10 null mice
but not CONV-WT at 28 days after ICR. Un-operated CONV-IL-10 null mice do not typically
develop small bowel disease [24,25]. While we do not yet know the precise mechanisms that
elicit post-surgical inflammation in the small intestine and anastomosis of CONV-IL-10 null
mice after ICR, a likely contributing factor is exposure of the anastomosis or small intestine
to microflora or luminal contents from the colon due to loss of ileo-cecal valve. A recent review
highlighted exposure to luminal agents including bacteria, as causative factors in post-surgical
disease in CD patients, particularly those with ileocolonic anastomosis [30]. The fact that GF-
IL-10 null mice do not develop inflammation after ICR supports this concept. However,
findings that inflammation develops in small intestine and anastomosis of CONV-IL-10 null,
but not CONV-WT mice, demonstrate that post-surgical small bowel inflammation occurs only
in IL-10 null mice with genetic susceptibility to IBD or ongoing IBD. SI and anastomosis are
typical sites of inflammation and fibrosis in CD patients after ileo-colonic resection [5,6,7,8].
While we must be cautious in extrapolating the findings in our animal model to post-surgical
disease in CD, ICR in CONV and GF-IL-10 null mice provides a new and unique model to
pursue future studies of the mechanisms of post-surgical inflammation including the role of
specific commensal microflora. It will be of significant interest for example to assess if specific
bacteria linked to recurrent disease in CD patients [21] induce post-surgical small bowel disease
in GF-IL-10 null mice after ICR.
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There is no consensus that typically employed post-surgical therapies such as
immunosuppressives or antibiotics reduce post-surgical disease recurrence in CD patients [6,
7] and nor is it clear whether newer therapies such as anti-TNFα impact on post-surgical disease
[31]. Our animal model of post-surgical inflammation provides a well-controlled experimental
model to test the effects of anti- TNFα and other emerging therapies such as probiotics [2,32,
33]. Modulation of luminal flora by probiotics [12,34,35,36,37,38] is a potential new therapy
for CD or post-surgical CD. Trials of single probiotics in CD [39,40] or post-surgical CD
[41] did not improve disease, leading to a consensus that more information is needed before
probiotics are used more widely in CD [15,34,38,42]. The animal models developed in our
study should prove particularly useful for future preclinical testing of probiotics during post-
surgical inflammation.
A common cause of surgery or repeat surgery in CD patients is stricture, caused by
fibrostenosing disease [5,6,7,8]. Much less is known about mechanisms of fibrosis or stricture
in CD than inflammation, and even less is known about mechanisms of post-surgical fibrosis
and stricture. Histological scoring and assays of collagen mRNA abundance demonstrate
fibrosis as well as inflammation in small intestine and anastomosis of IL-10 null mice after
ICR. Only IL-10 null and not WT mice given ICR developed post-surgical fibrosis in small
intestine distant from the site of surgery. However, WT given ICR and a subset of IL-10 null
and WT given transection, develop fibrosis at the anastomosis in the absence of detectable
inflammation. This suggests that development of post-surgical fibrosis in small bowel during
active inflammation may have distinct mechanisms than fibrosis at the anastomosis. Consistent
with this concept, post surgical fibrosis of small intestine, but not anastomosis, was associated
with increases in procollagen α1(I) mRNA indicative of ongoing collagen synthesis. A recent
review suggested that strictures which are inflammatory, fibrotic or both, may respond
differently to therapies such as anti-TNFα [31]. Testing of anti-TNFα or other therapies in
IL-10 null versus WT mice given ICR or control transection could therefore be very valuable
in differentiating effects of existing or new therapies on surgery-induced fibrogenic responses
at anastomosis versus fibrosis associated with active inflammation in small intestine. Our
findings that GF-IL-10 null mice given ICR exhibit only a low incidence and much less severe
fibrosis in small intestine or anastomosis, provide new in vivo evidence to support findings in
cultured cells that bacteria or bacterial products can drive fibrosis [22]. This sets the stage for
future studies where GF IL-10 null or WT mice given ICR or transection can be used as models
to evaluate the effects of specific bacteria on surgery or inflammation associated fibrosis.
Future studies are needed to fully define the time course and the mechanisms of post-surgical
inflammation and fibrosis in our IL-10 null ICR model. Initial examination of CONV-IL-10
null mice at 7 and 14 days after ICR demonstrates inflammation within submucosal as well as
mucosal layers in genetically susceptible IL-10 null mice but not WT early after ICR, indicating
that even early post-surgical inflammation is transmural in nature and occurs only in genetically
susceptible IL-10 null mice. Future studies aim to better characterize the cellular nature of
inflammatory infiltrate at different times after ICR and assess if fibrosis progresses to stricture.
It will also be of interest to study the consequences of ICR or ileal resection in spontaneous
ileitis models such as the SAMP1/Yit [43,44] and TNFΔARE [45] mice. Accumulating evidence
suggests that fibrostenosing disease has a genetic component with recent links to CARD15/
NOD2 or fractalkine receptor mutations [46,47]. Evaluation of fibrosis or inflammation after
ICR in mouse models carrying similar mutations could provide a useful experimental system
to directly define the roles of these genes in post-surgical inflammation or fibrosis.
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Figure 1. Schematic diagram of ileocecal resection (ICR) and tissue harvest
A schematic to indicate the ileocecal resection model where distal ileum, cecum and a small
portion of proximal colon are resected, then small intestine and colon joined at the anastomosis.
Schematic of tissue harvest shows one cm segment spanning the anastomosis and two one cm
segments of small intestine proximal to the anastomosis that were collected for histology (H)
or RNA extraction as indicated.
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Figure 2. Photographs of dissected small and large bowel from CONV-WT, CONV-IL-10 null or
GF-IL-10 null given transection (T) or ICR
Arrows indicate anastomosis. Note the significant small bowel and anastomosis inflammation
in CONV-IL-10 null given ICR compared with WT or GF-IL-10 null.
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Figure 3. Inflammation in small intestine and anastomosis of IL-10 null, but not WT, after ICR
Histograms show mean ± SEM for inflammation scores in the small intestine and anastomosis
of CONV-WT or CONV-IL-10 null mice after 28 days of no treatment (NoTx; WT: n=3; IL-10
null: n= 6), transection (T; WT: n=8; IL-10 null: n=6) or ileocecal resection (ICR; WT: n=10;
IL-10 null: n=11). a= p<0.05 compared with all other groups.
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Figure 4. Representative photomicrographs of H & E stained sections of IL-10 null or WT small
intestine to illustrate inflammation in CONV-IL-10 null mice after ICR
A) Small intestine of CONV-IL-10 null after NoTx, T or ICR and WT after ICR. Magnification
is shown at 10x to show inflammation in IL-10 mice following ICR, which is absent in NoTx,
T and WT controls. B) High power (20x) of small intestine (SI) or anastomosis (A) of IL-10
null mice after ICR to demonstrate transmural inflammation spanning the mucosa and muscle
layers. High power of anastomosis from WT shows little inflammation. C)
Immunohistochemical staining for CD3 in small intestine and colon of IL-10 null mice after
NoTx or ICR to demonstrate increased infiltration of T-cells into the lamina propria of small
intestine after ICR and T cell infiltration in colon. Small intestine of WT after ICR is also
shown to demonstrate no increase in T cells.
Rigby et al. Page 14













Figure 5. Serial analyses of inflammation in CONV-IL-10 null mice at 7, 14, and 28 days after ICR
Top: Low power 10x magnification and bottom high power 20x magnification of small
intestine of CONV-IL-10 null mice at 7, 14, 28 days after ICR compared with CONV-WT- at
7 days to illustrate that post-surgical small intestine inflammation in CONV-IL-10 null mice
is transmural even at early times after ICR and is sustained to 28 days, while WT show no
inflammation even at 7 days. Mean inflammation scores after ICR were: CONV-IL-10 null at
7 days 1.8±0.7 n=6; 14 days 2.3±0.7 n=4; and 28 days 2.3±0.2 n=6; WT at 7 days 0.5±0.1 n=8.
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Figure 6. Increased expression of TNF α mRNA in small intestine and anastomosis of CONV IL-10
null and not WT following ICR
Histograms show the mean ± SEM for TNF α mRNA abundance in CONV-WT or CONV-
IL-10 null small intestine after ICR or T compared with TNFα mRNA in a corresponding region
of SI from NoTx controls. Values are expressed as fold change vs. the mean value in WT,
NoTx. TNF α mRNA was significantly increased in both the small intestine and anastomosis
of IL-10 null mice after ICR when compared with all other groups (a= p ≤ 0.05). N=3 or more
animals in each group.
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Figure 7. Fibrosis scores in small intestine and anastomosis of CONV-IL-10 null and WT mice
Histograms show mean ± SEM for fibrosis scores in the small intestine and anastomosis of
WT and IL-10 null mice, 28 days after NoTx, T, or ICR (N=as in Figure 3). In small intestine
ICR caused significant fibrosis in IL-10 null, but not WT. Fibrosis at the anastamosis was not
restricted to IL-10 null mice, as WT mice also had significantly higher fibrosis scores than No
Tx controls (a= p ≤ 0.05 vs. all other groups; b= p ≤ 0.05 vs. all other SI groups; c= p ≤ 0.05
vs. NoTx).
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Figure 8. Representative photomicrographs of Sirius red stained sections of small intestine and
anastomosis of CONV IL-10 null and WT mice given NoTx, T or ICR
Photomicrographs of Sirius red stained sections of small intestine (10x magnification) or
anastomosis (4x magnification) to demonstrate the increased collagen deposition (stained red)
in small intestine of IL-10 null, but not WT after ICR. Fibrosis at the anastomosis is observed
in both IL-10 null and WT control mice after ICR, and in a subset of mice given T.
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Figure 9. Increased expression of collagen mRNA in small intestine and anastomosis of CONV
IL-10 null and not WT following ICR
Histograms show collagen mRNA abundance, expressed as fold change (mean ± SEM), in
IL-10 null and WT small intestine and anastomosis compared with small intestine of WT-NoTx
controls (N=3 or more per group). Consistent with histological scoring, collagen mRNA
abundance in CONV IL-10 null small intestine was significantly higher following ICR than in
NoTx, T or WT controls (a=p<0.05). Neither ICR nor T in IL-10 null or WT was associated
with significant increases in collagen mRNA at the anastomosis.
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Figure 10. No post-surgical inflammation in small intestine and anastomosis of GF IL-10 null mice
after ICR
Histograms show mean ± SEM for inflammation in the small intestine and anastomosis of GF-
IL-10 null after NoTx (n=6), T (n=6) or ICR (n=8). Inflammation score for CONV-IL-10 null
mice after ICR is shown (hashed bars) for comparison. Histological scoring revealed
significantly (p=0.009) reduced inflammation in GF-IL-10 null small intestine. Inflammation
also tended to be scored lower at the GF-IL-10 null anastomosis.
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Figure 11. Representative photomicrographs of H & E stained sections of small intestine and
anastomosis of GF IL-10 null mice
A) Photomicrographs of small intestine of GF-IL-10 null mice after NoTx, T or ICR and of
anastomosis after T or ICR to demonstrate little or no inflammation in GF-IL-10 null small
intestine and anastomosis following ICR (magnification at 10x). B) Immunohistochemical
staining for CD3 to demonstrate similar numbers of T-cells infiltrating into GF small intestine
following ICR, compared with NoTx.
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Figure 12. No significant fibrosis in small intestine or anastomosis of GF IL-10 null mice after ICR
Histograms show mean ± SEM for fibrosis scoring of the SI and anastomosis in GF- IL-10 null
after NoTx, T or ICR (N=as for Figure 9). Fibrosis score for CONV-IL-10 null mice after ICR
is shown for comparison (hashed bars). Histological scoring revealed significantly lower
fibrosis in GF-IL-10 null small intestine and anastomosis (a= p<0.05).
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Figure 13. Representative photomicrographs of Sirius red stained sections of small intestine and
anastomosis of GF-IL-10 null mice given NoTx, T or ICR
Photomicrographs of Sirius red stained sections of small intestine (10x magnification) or
anastomosis (4x magnification) to demonstrate low levels of collagen deposition (red stain) in
GF-IL-10 null mice following ICR.
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